The only European conference focusing specifically on competition law in the pharma sector.

Hear from Anna Vernet, Head of Unit, DG Competition, European Commission on their current priorities for the sector and ask your burning questions during the Q&A.

You will then have an opportunity to hear from representatives from key national competition authorities to ensure you are fully up to date with enforcement across Europe.

Inspect the current approach to mergers, including where we are with Article 22 after the ECJ judgment in Illumina/ Grail and the use of Article 102 after TowerCast, as well as broader issues relating to innovation and below-threshold deals.

Then gain practical tips on how to manage multijurisdictional transactions in light of merger control, FDI & FSR considerations.

Examine where we are with the EC’s update on draft Article 102 guidelines, what the Commission is trying to achieve and an update on recent excessive pricing decisions, exclusionary conduct, and rebates.

Discuss combination therapies, their challenges from a competition law perspective, and how the regulators are approaching them. What can the authorities do to facilitate greater entry of combination therapies into the market? Is there a need for a coordinated approach to combination therapies across EU?

Analyse the EC’s recent Vifor and Teva cases, how national regulators are approaching disparagement and what lessons can be learned for corporate compliance including promotional efforts, internal processes and codes of ethics.

Gain an update on recent EU and national developments including product hopping and 2^nd generation products.